机构:[1]Shu Lan HangZhou Hosp, Hangzhou, Peoples R China[2]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China浙江大学医学院附属第一医院[3]Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China广东省中医院[4]Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China浙江大学医学院附属第一医院[5]Shantou Univ Med Coll, Canc Hosp, Shantou, Peoples R China[6]Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China[7]MORE Hlth Inc, Foster City, CA USA[8]OrigiMed, Shanghai, Peoples R China
第一作者机构:[1]Shu Lan HangZhou Hosp, Hangzhou, Peoples R China[2]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China[3]Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China[4]Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China[5]Shantou Univ Med Coll, Canc Hosp, Shantou, Peoples R China[6]Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China[7]MORE Hlth Inc, Foster City, CA USA[8]OrigiMed, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Lin Guoling,Chen Zhang Xiao,Li Yong,et al.Pan-cancer genomic features of PIK3CA/PTEN and clinical response to everolimus in Chinese population[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.e24283.
APA:
Lin, Guoling,Chen, Zhang Xiao,Li, Yong,Qin, Yunsheng,Lv, Zhen...&Yao, Ming.(2018).Pan-cancer genomic features of PIK3CA/PTEN and clinical response to everolimus in Chinese population.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA:
Lin, Guoling,et al."Pan-cancer genomic features of PIK3CA/PTEN and clinical response to everolimus in Chinese population".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)